Sepsis Research Analysis
May’s sepsis research converged on host-directed immunometabolism, rapid resistance diagnostics, and actionable drug targets. Mechanistic studies nominated PLA2G5 as a circulating hemolytic driver, and revealed AIM2-driven PANoptosis as an itaconate-modulated node, while NLRP3 inhibition was enabled via repurposed ciclopirox. Kidney-protective metabolic control through the GATM–PDK4 axis suggests tractable organ-specific therapy. Machine learning from routine antibiograms (MALCA) delivered same-
Summary
May’s sepsis research converged on host-directed immunometabolism, rapid resistance diagnostics, and actionable drug targets. Mechanistic studies nominated PLA2G5 as a circulating hemolytic driver, and revealed AIM2-driven PANoptosis as an itaconate-modulated node, while NLRP3 inhibition was enabled via repurposed ciclopirox. Kidney-protective metabolic control through the GATM–PDK4 axis suggests tractable organ-specific therapy. Machine learning from routine antibiograms (MALCA) delivered same-day carbapenemase typing, accelerating appropriate therapy and stewardship.
Selected Articles
1. GATM alleviates sepsis-induced acute kidney injury via PDK4-mediated glycolytic reprogramming in renal tubular epithelial cells.
Cross-dataset and preclinical validation identify GATM as a protective regulator in sepsis-AKI; GATM overexpression suppresses PDK4-driven aerobic glycolysis, lowers lactate, increases ATP, and mitigates tubular/mitochondrial injury, while PDK4 overexpression reverses these effects.
Impact: Defines a tractable metabolic checkpoint (GATM–PDK4) for organ protection with in vivo rescue experiments, offering a concrete target for sepsis-AKI.
Clinical Implications: Supports targeting PDK4 or augmenting GATM to restore mitochondrial energetics in sepsis-AKI; requires dose-finding, biomarkers, and safety evaluation for translation.
Key Findings
- GATM is downregulated in proximal tubules across multiple datasets during S-AKI.
- AAV-mediated GATM overexpression improves renal function and reduces mitochondrial injury in LPS S-AKI.
- GATM downregulates PDK4 and glycolytic markers; PDK4 overexpression abolishes protection.
2. Secreted phospholipase PLA2G5 acts as a hemolytic factor in sepsis.
PLA2G5 is induced in intestinal cells during sepsis, circulates to drive intravascular hemolysis via erythrocyte membrane lipolysis; knockout or neutralizing antibody protects mice and human plasma levels predict severity/mortality.
Impact: Uncovers a circulating mediator with prognostic value and validates PLA2G5 as a druggable target using genetic and antibody blockade.
Clinical Implications: Positions plasma PLA2G5 for risk stratification and supports development of PLA2G5 blockade or hemolysis-mitigating adjuncts.
Key Findings
- PLA2G5 induction in colon cells and appearance as a circulating factor during sepsis.
- Pla2g5 knockout or neutralizing antibody protects mice and improves iron homeostasis.
- Plasma PLA2G5 is elevated in human sepsis and predicts severity/mortality.
3. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.
The FDA-approved antifungal ciclopirox olamine selectively inhibits NLRP3 by binding the NACHT domain, reducing ATPase activity and oligomerization, improving outcomes in murine sepsis models and showing ex vivo human activity.
Impact: Delivers an immediately testable repurposing strategy against a central inflammatory driver (NLRP3), accelerating the path to clinical translation.
Clinical Implications: Prioritize PK/PD, safety, and dose-ranging studies for systemic CPX in sepsis; if translatable, NLRP3 inhibition could blunt maladaptive inflammation in selected patients.
Key Findings
- Selective NLRP3 inhibition without affecting AIM2/NLRC4/Pyrin/NLRP1/6.
- CPX binds NACHT Y381, reduces ATPase activity, and prevents oligomerization.
- Therapeutic dosing improved outcomes in murine sepsis; ex vivo activity in human cells.
4. The alkylation of AIM2 by itaconate mediates macrophage PANoptosis during sepsis.
Pathologic itaconate covalently alkylates AIM2 at C113, stabilizing/activating it to drive ASC oligomerization and macrophage PANoptosis; mutational and in vivo data confirm the axis exacerbates systemic sepsis.
Impact: Links an immunometabolite to AIM2-driven PANoptosis, opening a novel druggable node for hyperinflammatory sepsis.
Clinical Implications: Suggests targeting AIM2 modification or downstream PANoptosis to preserve macrophages and limit hyperinflammation; human validation of itaconate/AIM2 status is needed.
Key Findings
- Itaconate alkylates AIM2 at C113, stabilizing and activating AIM2.
- Activated AIM2 triggers ASC oligomerization and PANoptosome assembly leading to PANoptosis.
- In vivo models show the itaconate–AIM2 axis worsens systemic sepsis.
5. Direct carbapenemase typing from disc diffusion antibiograms with MALCA (MAchine Learning CArbapenemase).
MALCA, a random-forest ML pipeline trained and externally validated on large antibiogram datasets, achieved >96% sensitivity/specificity for carbapenemase detection and >97%/>98% for common types, enabling rapid, reagent-free typing from routine labs.
Impact: Practical diagnostic innovation leveraging existing outputs to deliver same-day resistance mechanism typing, potentially reducing time to appropriate therapy in resistant sepsis.
Clinical Implications: Integration into lab workflows could guide early selection of targeted agents (e.g., ceftazidime–avibactam vs aztreonam–avibactam) and strengthen stewardship pending outcome-based implementation studies.
Key Findings
- Trained on 11,992 and externally validated on 8,514 isolates.
- ≥96% sensitivity/specificity for CPE detection; ≥97%/≥98% for OXA-48-like, NDM, and KPC typing.
- Outperformed established European/French CPE screening algorithms using only routine data.